Mono Pharmacare (NSE:MONOPHARMA) Short-Term Debt: ₹286 Mil (As of Sep. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:MONOPHARMA Mono Pharmacare Ltd NSE:MONOPHARMA
11 GF Score
Price ₹9.00
! 6 Warning Signs
View Full Analysis

What is Mono Pharmacare Short-Term Debt?

Mono Pharmacare NSE:MONOPHARMA +0.56% 11 Short-Term Debt is ₹286 Mil as of Sep. 2025. GuruFocus rates NSE:MONOPHARMA with a GF Score™ of 11/100. The stock has 6 warning signs investors should review.

Mono Pharmacare's Short-Term Debt for the quarter that ended in Sep. 2025 was ₹286 Mil.

Mono Pharmacare's quarterly Short-Term Debt increased from Sep. 2024 (₹268 Mil) to Mar. 2025 (₹276 Mil) and increased from Mar. 2025 (₹276 Mil) to Sep. 2025 (₹286 Mil).

Mono Pharmacare's annual Short-Term Debt increased from Mar. 2023 (₹225 Mil) to Mar. 2024 (₹243 Mil) and increased from Mar. 2024 (₹243 Mil) to Mar. 2025 (₹276 Mil).

Mono Pharmacare Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Mono Pharmacare Short-Term Debt Related Terms

Mono Pharmacare Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Mono Pharmacare's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mono Pharmacare Short-Term Debt Chart

Mono Pharmacare Annual Data
Trend Mar21 Mar22 Mar23 Mar24 Mar25
Short-Term Debt
50.95 49.26 224.87 243.16 275.99

Mono Pharmacare Semi-Annual Data
Mar21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25
Short-Term Debt Get a 7-Day Free Trial Premium Member Only 203.79 243.16 267.95 275.99 285.57
NSE:MONOPHARMA
11GF Score
Mono Pharmacare Ltd NSE:MONOPHARMA
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of ₹286 Mil mean?
Mono Pharmacare (NSE:MONOPHARMA) has a Short-Term Debt of ₹286 Mil as of Sep. 2025.
Is Mono Pharmacare's Short-Term Debt too high?
Mono Pharmacare's current Short-Term Debt is ₹286 Mil. Overall, Mono Pharmacare has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Mono Pharmacare's Short-Term Debt compare to competitors?
Mono Pharmacare's Short-Term Debt of ₹286 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Healthcare Providers & Services company?
A good Short-Term Debt depends on the Healthcare Providers & Services industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Mono Pharmacare's current Short-Term Debt is ₹286 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mono Pharmacare stock overvalued right now?
Mono Pharmacare (NSE:MONOPHARMA) has a current Short-Term Debt of ₹286 Mil. The current Short-Term Debt is ₹286 Mil. Mono Pharmacare's overall GF Score™ is 11/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Mono Pharmacare (NSE:MONOPHARMA), the current Short-Term Debt is ₹286 Mil as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Mono Pharmacare Business Description

Address 1A, Krinkal Apartment, Opposite Mahalaxmi Temple, Paldi, Ahmedabad, GJ, IND, 380007
Mono Pharmacare Ltd distributes a broad range of pharmaceutical products across India. Its portfolio includes antibiotics, antifungal medicines, cough and cold remedies, antacids, analgesics, nutraceuticals, skincare, antiseptics, cardiac and diabetic drugs, and cosmetic items. The company operates through contract manufacturing, sourcing products from various manufacturers and supplying them to healthcare providers and pharmacies. Revenue is generated through the sales and distribution of these pharmaceutical and healthcare products in the Indian market.
11GF Score

Get the complete analysis for NSE:MONOPHARMA

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹9.00
Price